Form sGnRHa/Ovaplant-2: Drug Inventory Form

For Use in sGnRHa (Ovaplant®) Clinical Field Trials Conducted under sGnRHa INAD 11-375

INSTRUCTIONS

1. Investigator should initiate a new form sGnRHa/Ovaplant-2 **immediately** upon receipt of each shipment of salmon gonadotropin releasing hormone analog.
2. Form sGnRHa/Ovaplant-2 should be updated whenever drug is used, transferred, or discarded.
3. Investigator should save all copies of this form until the end of the calendar year, at which time they should maintain all originals on file and send one copy of the completed form(s) to their Study Monitor. Within 10 days of receipt, the Study Monitor will ensure accuracy and send a copy to the Bozeman NIO for inclusion in the permanent file.
4. **Note:** Both Investigator and Study Monitor should sign and date Form sGnRHa/Ovaplant-2.

Qty of sGnRHa from previous page (mg) _____ Facility _____ Reporting individual _____

Date	Amount of new sGnRHa received (mg)	Lot number of sGnRHa received	ug sGnRHa per pellet	Study Number	Amount of sGnRHa used in treatment (mg)	sGnRHa transferred (mg)	sGnRHa discarded (mg)	sGnRHa remaining on hand (mg)	Inventory by (Initials)
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						
	xxxx	xxxx	xxxx						

Date Prepared: _____ **Investigator:** _____

Date Reviewed: _____ **Study Monitor:** _____